Your browser doesn't support javascript.
loading
Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score.
Pertusi, Dante A; O'Donnell, Gregory; Homsher, Michelle F; Solly, Kelli; Patel, Amita; Stahler, Shannon L; Riley, Daniel; Finley, Michael F; Finger, Eleftheria N; Adam, Gregory C; Meng, Juncai; Bell, David J; Zuck, Paul D; Hudak, Edward M; Weber, Michael J; Nothstein, Jennifer E; Locco, Louis; Quinn, Carissa; Amoss, Adam; Squadroni, Brian; Hartnett, Michelle; Heo, Mee Ra; White, Tara; May, S Alex; Boots, Evelyn; Roberts, Kenneth; Cocchiarella, Patrick; Wolicki, Alex; Kreamer, Anthony; Kutchukian, Peter S; Wassermann, Anne Mai; Uebele, Victor N; Glick, Meir; Rusinko, Andrew; Culberson, J Christopher.
Afiliación
  • Pertusi DA; 1 Modeling and Informatics, Merck & Co., Inc., West Point, PA, USA.
  • O'Donnell G; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Homsher MF; 3 Merck & Co., Inc., West Point, PA, USA.
  • Solly K; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Patel A; 3 Merck & Co., Inc., West Point, PA, USA.
  • Stahler SL; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Riley D; 3 Merck & Co., Inc., West Point, PA, USA.
  • Finley MF; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Finger EN; 3 Merck & Co., Inc., West Point, PA, USA.
  • Adam GC; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Meng J; 3 Merck & Co., Inc., West Point, PA, USA.
  • Bell DJ; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Zuck PD; 3 Merck & Co., Inc., West Point, PA, USA.
  • Hudak EM; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Weber MJ; 4 Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA.
  • Nothstein JE; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Locco L; 5 Discovery & Preclinical Development, GlaxoSmithKline, Collegeville, PA, USA.
  • Quinn C; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Amoss A; 3 Merck & Co., Inc., West Point, PA, USA.
  • Squadroni B; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Hartnett M; 2 Screening and Protein Sciences, Merck & Co., Inc., North Wales, PA, USA.
  • Heo MR; 6 Merck & Co., Inc., North Wales, PA, USA.
  • White T; 6 Merck & Co., Inc., North Wales, PA, USA.
  • May SA; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Boots E; 8 Discovery Sample Management, Merck & Co., Inc., North Wales, PA, USA.
  • Roberts K; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Cocchiarella P; 3 Merck & Co., Inc., West Point, PA, USA.
  • Wolicki A; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Kreamer A; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Kutchukian PS; 4 Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA.
  • Wassermann AM; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Uebele VN; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Glick M; 3 Merck & Co., Inc., West Point, PA, USA.
  • Rusinko A; 7 Automation and Engineering, Merck & Co., Inc., North Wales, PA, USA.
  • Culberson JC; 4 Discovery Sciences, Janssen Research and Development LLC, Spring House, PA, USA.
SLAS Discov ; 22(8): 995-1006, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28426940
ABSTRACT
High-throughput screening (HTS) is a widespread method in early drug discovery for identifying promising chemical matter that modulates a target or phenotype of interest. Because HTS campaigns involve screening millions of compounds, it is often desirable to initiate screening with a subset of the full collection. Subsequently, virtual screening methods prioritize likely active compounds in the remaining collection in an iterative process. With this approach, orthogonal virtual screening methods are often applied, necessitating the prioritization of hits from different approaches. Here, we introduce a novel method of fusing these prioritizations and benchmark it prospectively on 17 screening campaigns using virtual screening methods in three descriptor spaces. We found that the fusion approach retrieves 15% to 65% more active chemical series than any single machine-learning method and that appropriately weighting contributions of similarity and machine-learning scoring techniques can increase enrichment by 1% to 19%. We also use fusion scoring to evaluate the tradeoff between screening more chemical matter initially in lieu of replicate samples to prevent false-positives and find that the former option leads to the retrieval of more active chemical series. These results represent guidelines that can increase the rate of identification of promising active compounds in future iterative screens.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interfaz Usuario-Computador / Evaluación Preclínica de Medicamentos / Heurística Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: SLAS Discov Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interfaz Usuario-Computador / Evaluación Preclínica de Medicamentos / Heurística Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: SLAS Discov Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos